OverviewChartNewsTraderScreen

HSBC Call 110 BAYN 17.12.2025/  DE000TT8FS91  /

Frankfurt Zert./HSBC
2024-09-26  9:21:18 AM Chg.+0.002 Bid9:21:32 AM Ask9:21:32 AM Underlying Strike price Expiration date Option type
0.003EUR +200.00% 0.003
Bid Size: 20,000		 0.017
Ask Size: 20,000		 BAYER AG NA O.N. 110.00 EUR 2025-12-17 Call
TeleTrader 08-16 Bayer jumps 10% after Roundup court win
GlobeNewswire 08-02 Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire 07-11 AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire 06-25 AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
GlobeNewswire 05-30 Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire 05-30 BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 05-28 Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
TeleTrader 05-14 Bayer's sales in Q1 at €13.7 billion, down 4.3%
GlobeNewswire 05-02 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire 04-18 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire 04-16 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire 04-11 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire 04-09 AskBio Names Mansuo Shannon Chief Scientific Officer
GlobeNewswire 03-25 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire 03-14 Bayer and Aignostics to collaborate on next generation precision oncology
GlobeNewswire 03-06 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
TeleTrader 03-05 Bayer's Q4 sales at €11.9 billion
GlobeNewswire 03-04 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
TeleTrader 03-04 Earnings preview: Bayer, Broadcom among those in calendar
GlobeNewswire 02-15 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire 02-13 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire 02-13 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
TeleTrader 01-29 Bayer down over 5% after latest $2.25B Roundup ruling
TeleTrader 01-17 Bayer to cut jobs amid 'difficult situation'